Joint Global Coordinator & Joint Bookrunner
Kempen & Co acted as Joint Global Coordinator & Joint Bookrunner in Immunicum’s SEK 141.2m Capital Increase
Immunicum is a clinical-stage biopharmaceutical company developing off-the-shelf immune primers based on allogeneic dendritic cell biology to treat blood-borne and solid tumors. The company addresses key challenges in cancer therapy being difficult-to-treat tumors and tumors with a high risk of recurrence through unique approaches of intratumoral priming and cancer relapse vaccination.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: